ARK Investment Management LLC Buys 5,155 Shares of ARK Genomic Revolution ETF (BATS:ARKG)

ARK Investment Management LLC grew its stake in ARK Genomic Revolution ETF (BATS:ARKG) by 128.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 9,179 shares of the company’s stock after purchasing an additional 5,155 shares during the quarter. ARK Investment Management LLC’s holdings in ARK Genomic Revolution ETF were worth $301,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ARKG. JPMorgan Chase & Co. grew its stake in ARK Genomic Revolution ETF by 106.2% in the 4th quarter. JPMorgan Chase & Co. now owns 16,435 shares of the company’s stock worth $464,000 after acquiring an additional 281,148 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of ARK Genomic Revolution ETF by 11.2% during the second quarter. Wells Fargo & Company MN now owns 2,752,614 shares of the company’s stock valued at $93,837,000 after purchasing an additional 277,885 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of ARK Genomic Revolution ETF by 835.6% during the fourth quarter. SG Americas Securities LLC now owns 213,059 shares of the company’s stock valued at $6,990,000 after purchasing an additional 190,287 shares in the last quarter. Quantitative Investment Management LLC bought a new position in shares of ARK Genomic Revolution ETF during the second quarter valued at approximately $3,422,000. Finally, Tower Research Capital LLC TRC bought a new position in shares of ARK Genomic Revolution ETF during the third quarter valued at approximately $2,007,000.

ARK Genomic Revolution ETF Stock Performance

BATS ARKG opened at $28.56 on Thursday. The company’s 50-day simple moving average is $29.86 and its 200 day simple moving average is $28.76.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.